Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

IOV-3001

Fusion protein · Immune activation, directed at IL-2 receptor (IL2RA) · developed by IOVANCE BIOTHERAPEUTICS

Phase 1/2 Most advanced trial

IOVA Developer

1 Registered trials

What is IOV-3001?

IOV-3001 is a fusion protein combining modified interleukin-2 (aldesleukin) with the antibody palivizumab. The IL-2 moiety binds IL-2 receptor to activate cytotoxic T-lymphocytes and natural killer cells, inducing cytotoxic cytokines that enhance immune responses against tumor cells. It is being studied in melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Fusion protein
Targets: IL-2 receptor (IL2RA)
Mechanism: Immune activation, directed at IL-2 receptor (IL2RA)
Pathways: IL-2/IL-2R signaling, T-cell activation, NK cell activation
Therapy area: Oncology
Developer: IOVANCE BIOTHERAPEUTICS (IOVA)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06940739	Phase 1/2	Unresectable Melanoma	Recruiting	IOVA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic MelanomaOcular MelanomaUnresectable Melanoma

Other drugs acting on IL2RA

Aldesleukin FDA approved Anti-Thymocyte Globulin FDA approved Denileukin Diftitox FDA approved Camidanlumab Tesirine Phase 2

More from IOVANCE BIOTHERAPEUTICS

Lifileucel FDA approved IOV-2001 Phase 1 IOV-4001 Phase 1/2 IOV-5001 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IOVA page.

Follow IOVA, the company behind IOV-3001

See IOVA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IOVA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z